康惠制药(603139) - 2019 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company was CNY 10,298,741.89, an increase of 0.71% year-on-year[6]. - Operating revenue for the period reached CNY 87,523,087.15, reflecting a growth of 16.63% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 9,345,222.93, down 8.31% year-on-year[6]. - Basic and diluted earnings per share remained at CNY 0.10[6]. - The company reported a significant reduction in asset impairment losses, improving by 1746.91% to a loss of CNY -129,534.35 from CNY -7,013.57[19]. - The total profit for Q1 2019 was CNY 12,997,647.70, compared to CNY 12,758,089.99 in Q1 2018, marking an increase of 1.88%[31]. - The net profit for Q1 2019 was CNY 10,811,093.56, representing a slight increase of 1.44% from CNY 10,656,926.33 in Q1 2018[32]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,106,088,319.13, a decrease of 0.37% compared to the end of the previous year[6]. - The total assets decreased slightly to CNY 1,106,088,319.13 from CNY 1,110,188,511.01[22]. - The total liabilities decreased to CNY 901,648,212.21 from CNY 911,028,446.94[21]. - Total liabilities as of March 31, 2019, were CNY 94,524,262.45, down from CNY 113,000,604.82 at the end of 2018[26]. - Shareholders' equity as of March 31, 2019, was CNY 953,437,063.28, an increase from CNY 943,801,381.33 at the end of 2018[28]. - The company reported total liabilities of CNY 130,876,393.99, with current liabilities at CNY 120,681,137.91 and non-current liabilities at CNY 10,195,256.08[48]. Cash Flow - Net cash flow from operating activities was CNY -49,376,816.90, an improvement of 15.20% compared to CNY -58,230,503.20 in the previous year[6]. - Cash flow from operating activities improved by 15.20%, with a net outflow of CNY 49,376,816.90 compared to CNY 58,230,503.20 in the previous period[19]. - Cash inflows from operating activities totaled CNY 102,816,668.93, an increase of 35% compared to CNY 76,049,758.59 in Q1 2018[36]. - The net cash flow from investment activities was CNY 26,897,189.98, significantly higher than CNY 578,797.31 in Q1 2018[37]. - The company recorded cash inflows from financing activities of CNY 6,002,142.75, compared to CNY 310,665.59 in the previous year[37]. - The net cash flow from financing activities improved to CNY 2,217,059.92 from CNY -2,933,207.90 in Q1 2018[37]. Shareholder Information - The total number of shareholders at the end of the reporting period was 10,280[12]. - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., held 39,600,000 shares, accounting for 39.65% of the total shares[12]. Research and Development - R&D expenses rose by 48.62% to CNY 2,181,261.76 from CNY 1,467,721.78, reflecting increased investment in research and development[19]. - Research and development expenses for Q1 2019 were CNY 2,181,261.76, up from CNY 1,467,721.78 in Q1 2018, indicating a focus on innovation[29]. Inventory and Receivables - The total amount of other receivables increased by 192.46% to CNY 35,123,473.80 from CNY 12,009,650.65, primarily due to increased daily operational transactions[17]. - Inventory increased to CNY 90,347,211.79 as of March 31, 2019, compared to CNY 75,525,500.70 at the end of 2018, reflecting a growth of 19.6%[24]. Government Subsidies - The company received government subsidies amounting to CNY 58,499.99 during the reporting period[9].